Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Inovio Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: INO exceeded the US Biotechs industry which returned 39.3% over the past year.
Return vs Market: INO exceeded the US Market which returned 19.5% over the past year.
Price Volatility Vs. Market
How volatile is Inovio Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StIs Inovio Pharmaceuticals (NASDAQ:INO) Using Too Much Debt?
1 month ago | Simply Wall StIs Inovio Pharmaceuticals' (NASDAQ:INO) Share Price Gain Of 294% Well Earned?
2 months ago | Simply Wall StInovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Is Inovio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INO ($11.35) is trading below our estimate of fair value ($44.55)
Significantly Below Fair Value: INO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: INO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INO is overvalued based on its PB Ratio (9.7x) compared to the US Biotechs industry average (3.6x).
How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INO's revenue (42.4% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: INO's revenue (42.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INO's Return on Equity is forecast to be high in 3 years time
How has Inovio Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INO is currently unprofitable.
Growing Profit Margin: INO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 29.8% per year.
Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: INO has a negative Return on Equity (-120.19%), as it is currently unprofitable.
How is Inovio Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: INO's short term assets ($382.1M) exceed its short term liabilities ($38.0M).
Long Term Liabilities: INO's short term assets ($382.1M) exceed its long term liabilities ($218.8M).
Debt to Equity History and Analysis
Debt Level: INO's debt to equity ratio (42.7%) is considered high.
Reducing Debt: Insufficient data to determine if INO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if INO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Kim (51 yo)
Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr ...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD2.59M) is below average for companies of similar size in the US market ($USD4.44M).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
|CEO, President & Director||11.33yrs||US$2.59m||1.26% |
|Chief Financial Officer||18.33yrs||US$1.14m||0.074% |
|Chief Operating Officer||1.58yrs||US$1.26m||0.0071% |
|Chief Scientific Officer||1.58yrs||US$972.53k||0.026% |
|Director of Investor Relations||2.83yrs||no data||no data|
|Vice President of Communications & Strategic Relations||1.08yrs||no data||no data|
|Senior Vice President of Quality Assurance||no data||no data||no data|
|Senior Vice President of Clinical Operations & Global Integration||no data||no data||no data|
|Senior Vice President of Regulatory Affairs||no data||no data||no data|
|Senior Vice President of Engineering Development||no data||no data||no data|
|Senior Vice President of Research & Development||no data||no data||no data|
|Senior Vice President of Clinical Development||0.33yr||no data||no data|
Experienced Management: INO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|CEO, President & Director||11.33yrs||US$2.59m||1.26% |
|Independent Director||2.83yrs||US$127.56k||0.015% |
|Independent Director||1.75yrs||US$242.43k||0.0072% |
|Independent Director||0.75yr||no data||0% |
|Independent Chairman of Board of Directors||1.75yrs||US$162.56k||0.031% |
|Chairman of the Scientific Advisory Board & Director||20.75yrs||US$397.59k||0.49% |
|Member of Scientific Advisory Board||11.33yrs||no data||no data|
|Independent Director||1.58yrs||US$200.44k||0.0073% |
|Member of Scientific Advisory Board||8.58yrs||no data||no data|
|Member of Scientific Advisory Board||1.92yrs||no data||no data|
Experienced Board: INO's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.2%.
Inovio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Inovio Pharmaceuticals, Inc.
- Ticker: INO
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.901b
- Shares outstanding: 167.52m
- Website: https://www.inovio.com
Number of Employees
- Inovio Pharmaceuticals, Inc.
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1992|
|GBMB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1992|
|INO *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 1992|
|0A43||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1992|
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human p ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 23:39|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.